QuidelOrtho (QDEL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.13
- Estimate
- -$0.05
- Surprise
- +374.6%
- Revenue (period 2026-06-28)
- $630.9M
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
QuidelOrtho (QDEL) beat the -$0.05 estimate with diluted EPS of $0.13 — a large 374.6% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates QDEL Sell at 5.1/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +374.6% surprise compares with a +86.0% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Supplier: single and sole source suppliers
- Target reached (-10.8% upside)
- Quality below floor (2.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.97
- Price target
- $15.21
- Stop
- $12.99
- Upside to target
- +8.9%
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
QDEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $958.0M
- P/E (fwd)
- 9.7
- 52-week range
- $9.92–$35.58
- Off 52-week high
- 60.7%
- RSI (14)
- 45
- Volume vs avg
- 0.66×
- Score today
- 5.1/10